For nearly half of people diagnosed with lung cancer, immunotherapy can slow the disease but not stop it. Funded through a $4 million joint investment from the Canadian Cancer Society (CCS) and the Weston Family Foundation, a new clinical trial aims to change that.
Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML: A myeloMATCH Treatment Trial
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
Autologous Stem Cell Transplant in Peripheral T Cell Lymphoma that Achieved a First Complete Remission (CR1) Following Induction Therapy (PTCL-STAT)
Lanreotide for the Prevention of Postoperative Pancreatic Fistula
A new survey study SC32S, collecting sociodemographic data from clinical trial participants, has now opened across Canada. This study will help researchers understand the feasibility of using a survey to gather information about trial participants’ backgrounds and everyday lives.
Phase II Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for New Diagnosed Older Adults with IDH2 Mutant AML - A myeloMATCH Substudy
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
Investigating Precision Medicine in the Adjuvant setting: a phase III Clinical Trial in Biliary tract cancer (SAFIR IMPACT BTC)
LUNA-2: LND101 in Unresectable Non-Small Cell Lung Cancer: A Randomized Phase II Trial
RAINBO-ORANGE: Treatment of Endometrial Cancer Based On Molecular Features
Delayed Reduced Volume and Dose Elective Radiotherapy (REVERT) in Patients with HNSCC
The next CCTG Clinical Research Associate (CRA) Lunch and Learn training session will be on Wednesday Jun 24th, 2025, at 12 pm ET, covering the top
CCTG is delighted to celebrate the distinguished career and dedication of Dr Glenwood Goss, who's work was recognized at the 2026 Annual Spring Meeting of Participants last weekend in Toronto. Dr Goss was awarded the Dr. Joseph Pater Founder’s Award for Excellence in Clinical Trials Research presented to a clinical trials research investigator whose leadership and body of work has contributed to significant advances in the understanding, diagnosis, treatment, cure, and prevention of cancer.
The Team Awards for Phase III CCTG trials is presented to trial teams from member centres for performance in trial accrual, local activation timelines, compliance metrics and team performance is determined by the Executive IND Committee and Clinical Trials Committee.
We are pleased to inform you that the Canadian Cancer Trials Group (CCTG) is organizing our next Clinical Research Associate (CRA) Lunch and Learn training program, to be held on Wednesday, May 13th, 2026, at 12 pm ET on the topic: NCTN Clinical Trial Support Unit (CTSU) OPEN System and upcoming changes
Congratulations to Lynn Dwernychuk for being honoured with the CCTG Award for Excellence in Clinical Trials Conduct, presented to her last weekend at the Annual Spring Meeting of Participants. Lynn was recognized by her peers as an individual who exemplifies excellence in clinical trial operations and compliance. She serves as the Director of Clinical Research at the Saskatchewan Cancer Agency and holds an Adjunct Professorship with the College of Graduate Studies and Research at the University of Saskatchewan.
The CCTG Pharmacy Network is actively seeking pharmacy representation for the following:
CCTG is delighted to recognize the early career of Dr. Jelena Lukovic who was presented with the CCTG Dr. Ralph Meyer Phase III Young Investigator Award this past weekend at the Spring Meeting of Participants in Toronto. This award is given to an outstanding young investigator who is working on a CCTG Phase III clinical trial.She is the Canadian PI for the international NEEDS trial evaluating definitive chemoradiotherapy for squamous cell esophageal cancer.
Congratulations to Dr. Connor Wells who is a new investigator enrolling patients to the CRC.10 study at Alberta Health's Arthur J.E. Child Comprehensive Cancer Centre.
